首页> 外文期刊>Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia >Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis
【24h】

Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis

机译:年龄超过80岁与卒中溶栓后出血转化增加无关

获取原文
获取原文并翻译 | 示例
           

摘要

Thrombolysis trials have recruited few patients aged ≥80 years, which has led to uncertainty about the likely risk-to-benefit profile in the elderly. Leukoaraiosis (LA) has been associated with hemorrhagic transformation (HT) and increases with advanced age. We tested whether there were any independent associations between age, LA and HT. Consecutive patients treated with intravenous (IV) tissue plasminogen activator (tPA) were identified from a prospective database. LA on baseline CT scans was assessed by two independent raters using the modified Van Swieten Score (mVSS) (maximum score 8, severe >4). HT was assessed on routine 24 hour to 48 hour CT /MRI scans using the European Cooperative Acute Stroke Study criteria for hemorrhagic infarct (HI) or parenchymal hematoma (PH) and judged symptomatic by the treating neurologist as per Safe Implementation of Thrombolysis in Stroke criteria. There were 206 patients treated with IV tPA (mean age: 71.0 years; range: 24-92 years), of whom 65/206 (32%) were aged ≥80 years. Overall, HT occurred in 41/206 patients (20%), HI in 31, PH1 in four (one symptomatic) and PH2 in six (three symptomatic). Age was not associated with HT (any HT: odds ratio [OR] = 1.01; 95% confidence interval [CI] = 0.5-2.08; p = 0.99; PH: OR = 0.53; 95% CI = 0.12-2.3; p = 0.51). There was one patient with PH1 and one patient with PH2 in 65 patients ≥80 years, both asymptomatic. LA was present in 112/208 (54%), and severe in 16.5%. LA increased with age (p < 0.001) but was not associated with PH (any LA: OR = 0.83; 95% CI = 0.25-2.8; p = 0.99; severe LA: OR = 0.54, 95% CI = 0.09-3.5; p = 0.99). Age ≥80 years or LA did not increase the risk of HT (including PH) after thrombolysis, although LA increased with age. Neither factor should exclude otherwise eligible patients from tPA treatment.
机译:溶栓试验招募了年龄在80岁以上的极少数患者,这导致了老年人可能的风险收益特征的不确定性。白细胞增多症(LA)与出血性转化(HT)相关,并随着年龄的增长而增加。我们测试了年龄,LA和HT之间是否存在任何独立的关联。从前瞻性数据库中识别出接受静脉内(IV)组织纤溶酶原激活剂(tPA)治疗的连续患者。由两名独立评估者使用改良的Van Swieten评分(mVSS)(最高评分8,严重> 4)评估基线CT扫描的LA。使用欧洲合作性急性卒中研究标准对出血性梗塞(HI)或实质性血肿(PH)进行常规24小时至48小时CT / MRI扫描评估HT,并由神经科医师根据卒中溶栓安全实施标准对症状进行判断。接受静脉tPA治疗的206例患者(平均年龄:71.0岁;范围:24-92岁),其中65/206岁(32%)的年龄≥80岁。总体而言,HT发生在41/206例患者中(20%),HI发生在31例中,PH1发生在4例(有症状)中,PH2发生在6例(3例有症状)中。年龄与HT无关(任何HT:优势比[OR] = 1.01; 95%置信区间[CI] = 0.5-2.08; p = 0.99; PH:OR = 0.53; 95%CI = 0.12-2.3; p = 0.51)。 65岁≥80岁的患者中有1名PH1患者和1名PH2患者,均无症状。 LA占112/208(占54%),严重者占16.5%。 LA随年龄增加(p <0.001)但与PH不相关(任何LA:OR = 0.83; 95%CI = 0.25-2.8; p = 0.99;严重LA:OR = 0.54,95%CI = 0.09-3.5; p = 0.99)。年龄≥80岁或LA不会增加溶栓后HT(包括PH)的风险,尽管LA会随着年龄而增加。这两个因素均不应将其他符合条件的患者排除在tPA治疗之外。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号